**Core tip:** We investigated the association between maf protein K (*MAFK*), polymorphisms and ulcerative colitis in Japan. Both rs4268033 and rs3735656 minor allele homozygotes were significantly associated with the susceptibility to ulcerative colitis (UC) development. In addition, rs4268033 minor allele homozygote was significantly associated with all phenotypes of UC except the phenotype with younger age onset. Our results provided the first evidence that *MAFK* genetic polymorphisms were significantly associated with the susceptibility to UC development.

INTRODUCTION
============

The number of inflammatory bowel disease (IBD) patients in several Asian countries, including Japan and China, has recently rapidly increased with adaptation of a westernization life style and diet\[[@B1]\]. Ulcerative colitis (UC) is a representative IBD whose exact etiology is unclear, but environmental and genetic factors are implicated in its onset\[[@B2],[@B3]\]. UC is a nonspecific inflammatory disease possibly involving the colonic mucosa spanning from the rectum to the cecum. It has been clarified that the degradation of inflammation and immune response related molecules prescribed genetically participate\[[@B4]\]. UC is a multifactorial, polygenic disease with probable genetic heterogeneity, and the associations between the polymorphisms of various genes and UC have been studied\[[@B5],[@B6]\].

Reactive oxygen species (ROS) are involved in promoting inflammation in various diseases, including UC\[[@B7],[@B8]\]. Nuclear factor-erythroid 2-related factor 2 (Nrf2) plays an important role in the removal of ROS\[[@B9],[@B10]\]. Nrf2 cannot induce anti-oxidant enzymes such as heme oxygenase-1 (HO-1) and peroxiredoxin 1 alone, and shows transcriptional activity when hetero-dimerized with small musculoaponeurotic fibrosarcoma (Maf)\[[@B11]\]. Thus, it has been clarified that small Maf proteins are regulated transcription factors through heterodimer formation, with Nrf2 and BTB And CNC Homology 1 (Bach1)\[[@B12]\], although small Mafs do not contain an obvious transcriptional activation domain\[[@B13]\]. We previously reported a significant association between Nrf2 genetic polymorphisms and susceptibility to UC\[[@B14]\].

In the present study, we investigated the association between genetic polymorphisms of MAFK, one of the small Mafs, and UC susceptibility in a Japanese population.

MATERIALS AND METHODS
=====================

Clinical samples
----------------

The study was performed using a population comprising 226 patients with UC (UC cases) and 748 subjects without lower abdominal symptoms, diarrhea or hematochezia (controls). In addition, as the second controls, we prepared 360 subjects, who have an irregular bowel movement without abnormal lower endoscopic findings (IBM controls). UC was diagnosed according to standard clinical, endoscopic, radiological, and histological criteria\[[@B15]\]. Genomic DNA was isolated from peripheral blood using FlexiGene DNA Kit (QIAGEN GmbH, Hilden, Germany).

The Ethics Committees of Fujita Health University and Kanazawa Medical University approved the protocol, and written informed consent was obtained from all participating subjects.

Classification
--------------

According to their clinical courses, UC cases were classified into 2 types: continuous, or not continuous, disease (*i.e*., relapsing or only one episode)\[[@B16]\]. UC patients were also classified by endoscopic findings as total or not total colitis (left sided, distal colitis) according to the location and extension of the inflammatory lesions. In addition, the cases were classified into two groups according to the past highest UC disease activity index (UCDAI) during the course of the disease (≤ 8 or ≤ 9)\[[@B17]\].

Selection of single nucleotide polymorphisms of MAFK
----------------------------------------------------

There are two large linkage disequilibrium blocks within 20kbp of *MAFK* with a Hardy-Weinberg equilibrium (HWE) *P* value of above 0.05 and a minor allele frequency of above 0.05. We selected rs4268033 G\>A and rs3735656 T\>C (\*910 T\>C) as a Tag single nucleotide polymorphism (SNP) in each block and another SNP, rs10226620 C\>T (\*1506 C\>T), located in the 3'-UTR where several microRNA bind, was also selected.

Genotyping of polymorphisms
---------------------------

Polymorphisms were genotyped using the PCR-SSCP method as reported previously\[[@B14],[@B18]\]. The PCR and SSCP conditions are shown in Table [1](#T1){ref-type="table"}. All PCR reactions were carried out in a volume of 20 μL containing 0.1 μg of genomic DNA using Takara HS Taq (TAKARA Bio Inc., Japan). SSCP was carried out using a GenePhor DNA separation system with GeneGel Excel 12.5/24 (GE Health Care Bio-Sciences AB, Sweden) at 6 °Ctemperature, and then the denatured single strand DNA bands were detected using a DNA Silver Staining Kit (GE Health Care Bio-Sciences AB).

###### 

Condition of PCR and SSCP

  **Primer set**                      **PCR condition**                    **SSCP temperature**
  ----------------------------------- ------------------------------------ ----------------------
  (rs4268033)                                                              
  5\'-TAATCCCAACTCGCAGCATCTGTGT-3\'   96 °C 15 s, 60 °C 30 s, 72 °C 30 s   6 °C
  5\'-GGTCTGACTTAGCTGGGGAAAGTGC-3\'   35 cycle                             
  (rs3735656)                                                              
  5\'-ATCTCAGCGGACACAGGCAGGA-3\'      96 °C 15 s, 54 °C 40 s, 72 °C 30 s   6 °C
  5\'-CTGCACTGACCACAGTTGGTGAGAA-3\'   35 cycle                             
  (rs10226620)                                                             
  5\'-GTCCCTCCTGTGACTGGGGTCTCT-3\'    96 °C 15 s, 60 °C 30 s, 72 °C 30 s   6 °C
  5\'-AGGCACCACCTTGCAGGTCTTATGT-3\'   35 cycle                             

Statistical analysis
--------------------

HWE was assessed by *χ*^2^ statistics. The age data were expressed as mean ± SD. Mean ages between the cases and the controls was compared by Student's *t*-test, and the male/female ratio was compared by Fisher's exact test. The allele counts and the distribution of genotype were compared between the two groups by a 2 × 2 table using Fisher's exact test. The odds ratios (OR) and 95%CI were calculated by logistic regression with adjustment for age and gender. A probability value of less than 0.05 was considered statistically significant in all analyses.

RESULTS
=======

Characteristics of the study subjects and frequencies of the genotypes
----------------------------------------------------------------------

The characteristics of the subjects in this study are summarized in Table [2](#T2){ref-type="table"}. The mean ages of both controls and IBM controls were significantly higher than that of the UC cases. The male/female ratio of IBM controls was significantly lower than those of the controls and UC cases. Single strand DNAs of all genotypes were clearly separated by SSCP (Figure [1](#F1){ref-type="fig"}). The distribution of genotypes in the controls was in Hardy-Weinberg equilibrium (rs4268033, rs3735656 and rs10226620: *P* = 0.25, *P* = 0.21 and *P* = 0.87, respectively). The ratio of the mutant homozygote (AA genotype) of rs4268033 was significantly higher in the UC cases compared to the controls and IBM controls (*P* = 0.0005 and \< 0.0001, respectively). However, no significant differences in the distributions of rs3735656 and rs10226620 genotypes were observed. There were no significant differences in the distributions of genotypes between the controls and IBM controls.

![Images of PCR-SSCP using clinical samples. Single strand DNAs were clearly separated by SSCP. The genotypes could be determined.](WJG-23-5364-g001){#F1}

###### 

Characteristics of the subjects and allelic frequency

                      **Controls**   **IBM controls**                          **UC cases**
  ------------------- -------------- ----------------------------------------- ---------------------------------------------
  Number of sample    748            360                                       226
  Mean age ± SD       57.1 ± 17.0    58.5 ± 14.5                               40.7 ± 14.2[a](#T2FN1){ref-type="table-fn"}
  (age of onset)                                                               (33.6 ± 13.5)
  Male:female         438:310        165:195[b](#T2FN2){ref-type="table-fn"}   125:101
  rs4268033 G\>A                                                               
  GG                  366            184                                       101
  GA                  324            156                                       89
  AA                  58             20                                        36[c](#T2FN3){ref-type="table-fn"}
  A allele freqency   29.40%         27.20%                                    35.6%[d](#T2FN4){ref-type="table-fn"}
  rs3735656 T\>C                                                               
  TT                  329            168                                       103
  TC                  346            162                                       90
  CC                  73             30                                        33
  C allele freqency   32.90%         30.80%                                    34.50%
  rs10226620 C\>T                                                              
  CC                  345            171                                       104
  CT                  328            159                                       94
  TT                  75             30                                        28
  T allele freqency   32.00%         30.40%                                    33.20%

*P* \< 0.0001 *vs* controls and IBM controls;

*P* \< 0.0001 *vs* controls and *P* = 0.027 *vs* UC cases;

*P* = 0.0005 *vs* controls and *P* \< 0.0001 *vs* IBM controls;

*P* = 0.015 *vs* controls and *P* = 0.0027 *vs* IBM controls. UC: Ulcerative colitis.

Association between MAFK polymorphisms and UC susceptibility
------------------------------------------------------------

When the controls was compared with UC cases, logistic regression analysis after adjustment for age and gender showed that the rs4268033 mutant homozygote (AA genotype) was strongly associated with susceptibility to UC (OR = 2.63, 95%CI: 1.61-4.30, *P* = 0.0001; Table [3](#T3){ref-type="table"}), and the rs3735656 mutant homozygote (CC genotype) was also significantly associated with UC susceptibility (OR = 1.81, 95%CI: 1.12-2.94, *P* = 0.015). When IBM controls was compared with UC cases, similar findings were obtained (OR = 3.54, 95%CI: 1.82-6.88, *P* = 0.0002 and OR = 2.14; 95%CI: 1.16-3.95, *P* = 0.015, for rs4268033 and rs3735656, respectively). No significant association between rs10226620 and UC was seen. The influence of *MAFK* genotypes on the symptoms from irregular bowel movement did not seem to be large.

###### 

Association between *MAFK* polymorphisms and ulcerative colitis

                       **Genotype (*n*)**   **AA *vs* others**   **Genotype (*n*)**   **CC *vs* others**                                                **Genotype (*n*)**   **TT *vs* others**                                                                                                                            
  -------------------- -------------------- -------------------- -------------------- -------------------------------- -------------------------------- -------------------- -------------------- ---- -------------------------------- ------------------------------- ----- ----- ---- --------------------------------- ---------------------------------
  rs4268033 G\>A                                                                                                                                                                                                                                                                                                           
  Controls (748)       366                  324                  58                   Reference                        \-                                                                                                                                                                                                  
  IBM controls (358)   184                  156                  18                   0.682 (0.402-1.16); *P* = 0.16   Reference                                                                                                                                                                                           
  UC cases (226)       101                  89                   36                   2.63 (1.61-4.30); *P* = 0.0001   3.54 (1.82-6.88); *P* = 0.0002                                                                                                                                                                      
  rs3735656 T\>C                                                                                                                                                                                                                                                                                                           
  Controls (748)                                                                                                                                        329                  346                  73   Reference                        \-                                                                                 
  IBM controls (358)                                                                                                                                    168                  162                  28   0.789 (0.503-1.24); *P* = 0.30   Reference                                                                          
  UC cases (174)                                                                                                                                        103                  90                   33   1.81 (1.12-2.94); *P* = 0.015    2.14 (1.16-3.95); *P* = 0.015                                                      
  rs10226620 C\>T                                                                                                                                                                                                                                                                                                          
  Controls (748)                                                                                                                                                                                                                                                        345   328   75   Reference                         \-
  IBM controls (358)                                                                                                                                                                                                                                                    171   159   28   0.764 (0.488-1.20); *P* = 0.24    Reference
  UC cases (174)                                                                                                                                                                                                                                                        104   94    28   1.37 (0.822 - 2.28); *P* = 0.23   1.57 (0.827 - 3.00); *P* = 0.17

UC: Ulcerative colitis.

Association between rs4268033 and UC phenotypes
-----------------------------------------------

The observed strong association between rs4268033 and UC susceptibility prompted us to investigate an association between this SNP and UC phenotypes. The rs4268033 genotype was only associated with UC cases with onset after 21 years of age. Regarding as clinical type, disease extension, the past history of hospitalization and the past maximum UCDAI score, rs4268033 was significantly associated with each phenotype of UC (Table [4](#T4){ref-type="table"}).

###### 

Association between rs4268033 and phenotype of ulcerative colitis

                            **Genotype (*n*)**   **AA *vs* others**                            
  ------------------------- -------------------- -------------------- ---- ------------------- --------
  Controls (748)            366                  324                  58   Reference           \-
  Age of onset                                                                                 
  20 (31)                   16                   12                   3    2.06 (0.499-8.52)   0.32
  21 (176)                  76                   71                   29   2.51 (1.51-4.19)    0.0004
  Unknown (19)                                                                                 
  Clinical type                                                                                
  Not continuous (124)      51                   52                   21   2.92 (1.63-5.25)    0.0003
  Continuous (97)           46                   36                   15   2.32 (1.20-4.48)    0.012
  Unknown (5)                                                                                  
  Extension                                                                                    
  Not total colitis (115)   50                   46                   19   2.72 (1.48-5.00)    0.0013
  Total colitis (105)       49                   41                   15   2.18 (1.14-4.16)    0.019
  Unknown (6)                                                                                  
  Hospitalization                                                                              
  None (139)                59                   59                   21   2.34 (1.32-4.14)    0.0035
  One time £ (76)           36                   27                   13   2.91 (1.42-5.97)    0.0034
  Unknown (11)                                                                                 
  Past max. UCDAI score                                                                        
  8 (135)                   56                   58                   21   2.41 (1.36-4.27)    0.0025
  9 (81)                    40                   27                   14   3.01 (1.49-6.05)    0.002
  Unknown (10)                                                                                 

UC: Ulcerative colitis.

DISCUSSION
==========

Three small Maf proteins have been identified to date: MafG, MafK and MafF were identified\[[@B19]\]. These three Maf proteins have high homology and form homodimers or heterodimers with each another and also heterodimers with a group of other b-Zip proteins\[[@B20]\]. Previous studies using knockout mice showed that MafG^-/-^/K^-/-^ mice are die by the peri- or postnatal stage, whereas both MafF^-/-^/G^-/-^ and MafF^-/-^/K^-/-^ mice are viable and fertile\[[@B21]-[@B23]\]. We therefore selected the two small Mafs, MafG and MafK, because of their apparent importance in biology. In HapMap-JPT, there are large linkage blocks of SNPs around *MAFK* but not around *MAFG*. Furthermore, previous studies revealed that MafK-Bach1 controls the expression of a subset of oxidative stress-inducible genes, such as HO-1 and ferritins\[[@B24]\], whereas MafK-Nrf2 heterodimer activates their expression\[[@B25]\]. We therefore suspected that *MAFK* genetic variations might affect the development and process of inflammatory diseases, including UC.

Our results provide the first evidence that *MAFK* genetic polymorphisms are significantly associated with susceptibility to UC in the Japanese population. In these polymorphisms, the rs4268033 G\>A minor allele homozygote is closely associated with an increased risk for the development of UC. The allele frequencies of rs4268033 and rs10226620 in our controls, which were in HWE, were the same as that in the Japanese population reported in the HapMap database (*P* = 0.73 and 0.39, respectively). However, the distribution of rs3735656 genotype in our controls was different from that in HapMap-JPT (*P* = 0.011). The distribution of rs3735656 in our controls is in HWE (*P* = 0.21) whereas it is not in HapMap-JPT (*P* = 0.025). The cause of this discrepancy is unknown, but we believe that rs3735656 is worthy of further examination.

There are few reports linking *MAFK* genetic variations and clinical disease susceptibility\[[@B26],[@B27]\]. Nanashima et al\[[@B26]\] reported that the mutant allele of rs4720833, located in the same linkage block as rs4268033, is significantly associated with anti-tuberculosis drug induced hepatotoxicity susceptibility, whereas rs3808337, located in the same block as rs3735656, is not associated. This suggests that the rs4720833 mutant genotype might be associated with an increased risk of drug-induced injury *via* alteration of the toxicity of drug metabolites, although the detailed mechanisms remain unclear. Similarly, in our study, the rs4268033 mutant homozygote was strongly associated with UC susceptibility. In addition, this genotype was associated with all phenotypes of UC except age of onset. These findings suggest that rs4268033 may be associated with the development but not the progression of UC. The lack of association of early onset with UC may be due to the small number of cases and/or the younger controls.

It is not clear how rs4268033 participates in the development of UC. Small Maf proteins are transcription factors localized to the nucleus that dimerize with CNC family proteins, including Nrf2 and Bach1\[[@B13]\]. Small Maf-Bach1 heterodimers are removed from antioxidant-responsive element (ARE) by oxidative stress, and small Maf-Nrf2 heterodimers replace and bind to ARE, leading to the activation of antioxidant enzyme expression. Therefore, our data suggest that rs4268033 may act as a repressor for the expression of small Maf (dimerized with Nrf2) and/or as an activator for the expression of small Maf (dimerized with Bach1), resulting in association with UC susceptibility. Another possibility is that the mechanism involves the inflammatory response. Overexpression of MafK protein in T cells decreased T-cell proliferation and interleukin-2 (IL-2) secretion\[[@B28]\]. Therefore, IL-2 secretion, resulting in persistent inflammation, may be increased by the diminished expression of MafK protein in the rs4260833 mutant homozygote. However, the presence of enhancers or repressors in the genome region containing the linkage block with rs4268033 remains unknown. In addition, the downregulation of Nrf2 or upregulation of Bach1 in UC patients with the rs4268033 mutant homozygote should be verified by further studies.

There are some clinical limitations in our study. We recruited patients who visited our hospital for various reasons and therefore the mean age of the controls was relatively high. Age-matched subjects with no symptom are essential for the control group. In addition, the UC treatment regimens were not standardized, possibly affecting the clinical type and extent of inflammation observed. Furthermore, we had no data on the effects of *MAFK* gene polymorphisms on the expressions of MafK protein. Our study was a case-control studyand therefore further examination is necessary regarding this point. The major problem in this study is the relatively small sample size, especially the number of UC cases. A larger cohort will be required to clearly assess the association of genetic variation with disease susceptibility. Finally, the design of this study used only samples stored at a single center and were analyzed retrospectively.

In conclusion, the present study demonstrated that *MAFK* polymorphisms are significantly associated with susceptibility to UC. In particular, the rs4268033 minor homozygote is strongly associated with increased risk for the development of UC.
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